Table 1.

Characteristics of patients on EGFR inhibitor clinical trials who demonstrated an objective response

Case noAge at start of therapySexRacePrimary siteHistology*Smoking historyPrior therapyTreatmentResponseDuration of response (mo)Overall survival (mo)
150FWOC (tongue)VC4CRT, CTG 500 mgPR11.018
251MWOP (pharynx)PD3CTG 500 mgPR3.13.2
353MWOC (buccal)PD2CRTG 500 mgCR4.76
464MWOP (BoT)PD1CRTG 500 mgPR8.520
572MWSGLMD5CRTG 500 mgMinor9.037.4
662MWOP (pharynx)WD4CRTG 250 mgPR5.55.5
775FWOC (buccal)MD4CRTE 150 mg + B 15 mg/kgCR>8.0§>8.0
859MWOP (tonsil)MD-PD3CRT, CTG 500 mgPR47
  • NOTE: Response was assessed using the Response Evaluation Criteria in Solid Tumors in all patients, and all responses were verified by independent review. Duration of response is defined from first evidence of response until first evidence of disease progression measured in months. Overall survival is defined from start of therapy until death measured in months.

    Abbreviations: M, male; F, female; W, White; OC, oral cavity; OP, oropharynx; AR, alveolar ridge; BoT, base of tongue; SGL, supraglottic larynx; VC, verrucous carcinoma; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; CRT, chemoradiotherapy; CT, chemotherapy alone; G, gefitinib; E, erlotinib; B, bevacizumab; PR, partial response; CR, complete response.

  • * Only patients with squamous cell carcinoma were eligible to participate in the clinical trials.

  • 1, never used tobacco products; 2, used pipe, cigar, or chewing tobacco; 3, <20 pack-years cigarette use; 4, 20-40 pack-years cigarette use; 5, >40 pack-years cigarette use. Pack years is defined as the number of packs smoked per day multiplied by the number of years smoked.

  • All EGFR-TKIs were administered orally once daily without interruption. Bevacizumab was administered intravenously every 3 weeks.

  • § This patient remains on therapy at time of article submission.